Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 453-480-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Effects on fertility
Description of key information
No study available.
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
Two prenatal developmental toxicity (dermal) studies are available. One study result in NOAEL of 2000 mg/kg bw and the second one in a NOAEL < 800 mg/kg bw.
One prenatal developmental toxicity (oral) is available, which results in NOAEL of 1000 mg/kg bw.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Remarks:
- 2 substances are available for read across
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- see the attached justification in section 13 for details.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Remarks on result:
- other: Fatty acids, C5-9, tetraesters with pentaerythritol (CAS 67762-53-2)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- local
- Effect level:
- 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Remarks on result:
- other: 2,2-bis[(octanoyloxy)methyl]butyl decanoate (CAS 11138-60-6)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Remarks on result:
- other: 2,2-bis[(octanoyloxy)methyl]butyl decanoate (CAS 11138-60-6)
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- developmental
- Effect level:
- 800 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
- Remarks on result:
- other: Fatty acids, C5-9, tetraesters with pentaerythritol (CAS 67762-53-2)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- < 800 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
- Remarks on result:
- other: Fatty acids, C5-9, tetraesters with pentaerythritol (CAS 67762-53-2)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
- Remarks on result:
- other: 2,2-bis[(octanoyloxy)methyl]butyl decanoate (CAS 11138-60-6)
- Key result
- Abnormalities:
- not specified
- Key result
- Developmental effects observed:
- not specified
- Conclusions:
- The substance, CAS: 70851-04-6; EC: 453-480-2, is analogous to the substances to be read across to, in terms of basic form, and the degree of substitution of functional groups is not considered to effect the proposed read across for the endpoint of developmental toxicity/teratogenicity. Based on the available information to read across to, the substance is not expected to cause developmental toxcitiy / teratogenicity.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions; few details on test substance given, no analysis of the test compound
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- few details on test substance given, no analysis of the test compound
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Kingston, NY
- Age at study initiation: young adult
- Weight at study initiation: Mean of the maternal body weight: 226 g (Vehicle), 225 g (200 mg/kg bw/day), 227 g (600 mg/kg bw/day), 226 g (2000 mg/kg bw/day)
- Fasting period before study: No
- Housing: Virgin females were cohabitated with singly-housed male rats, one male per female rat for a maximum of 5 days and returned to individual housing in stainless steel wire-bottomed cages after mating.
- Diet: Certified Rodent Diet No. 5002 (PMI Feeds Inc. St.Louis, MO), ad libitum
- Water: water passaged through a reverse osmosis membrane with chlorine added as a bacteriostat, ad libitum
- Acclimation period: yes, period not mentioned
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25
- Humidity (%): 30 - 70
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- dermal
- Vehicle:
- corn oil
- Details on exposure:
- TEST SITE
- Area of exposure: The back of the animals from the shoulders to the hip joints and extended ventrolaterally from the dorsal midline on each side (5x7 cm)
- % coverage: approx. 10% of the body surface
- Type of wrap if used: occlusive, gauze pad secured with Vetrap or Micropore tape
- Time intervals for shavings or clipplings: during acclimatization period
REMOVAL OF TEST SUBSTANCE
- Washing (if done): exposed area was wiped with a dermal wipe pad dampened with aqueous 1% solution of soap and then patted dry with a second clean pad
- Time after start of exposure: 6 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2 mL/kg
- Concentration (if solution): 200, 600, and 2000 mg/kg/day
- Constant volume or concentration used: yes
VEHICLE
- Amount(s) applied (volume or weight with unit): 2 mL/kg
- Concentration (if solution): up to 100% (vehicle control)
USE OF RESTRAINERS FOR PREVENTING INGESTION: yes, Elizabethan collar - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1/1
- Length of cohabitation: maximum 5 days
- Further matings after two unsuccessful attempts: Not applicable
- Verification of same strain and source of both sexes: No Data
- Proof of pregnancy: Both, vaginal plug and/or sperm in vaginal smear were referred to as Day 0 of pregnancy - Duration of treatment / exposure:
- Treatment on Gestation Days (GD) 6 - 15
- Frequency of treatment:
- Daily
- Duration of test:
- Termination of the study by CO2 inhalation on GD 20.
- Remarks:
- Doses / Concentrations:
200, 600 and 2000 mg/kg bw/day
Basis:
nominal conc. - No. of animals per sex per dose:
- 25
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose dependent occurrence of skin irritation. Higher levels than 2000 mg/kg bw/day might be expected to produce marked irritation thereby compromising the interpretaion of developmental results.
- Rationale for animal assignment (if not random): Computer-generated randomization by weight (Barlett´s test for homogeneity) such that the groups were not statistically different (5% significance level) from each other. - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Animals were checked for mortality twice daily during the treatment period and daily thereafter.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Animals were checked for signs of reaction to treatment and/or symptoms of illness once daily before treatment, approx. 60 min after treatment during the dosing period. The dosing site was examined daily prior to substance application for signs of skin irritation according to Draize.
BODY WEIGHT: Yes
- Time schedule for examinations: Recorded on GD 0 and daily during the treatment period.
FOOD CONSUMPTION AND COMPOUND INTAKE : Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg b.w./day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
- Organs examined: The uterus, uterine contents, position of the fetuses in the uterus and number of corpora lutea. Number and distribution of intrauterine implantations were classified as live or death fetuses, late intrauterine deaths (resorptions) and early intrauterine resorption sites. Live fetuses were sexed and further examined (see below). - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: Yes: half per litter (the heads of the animals used for soft tissue examinations) - Statistics:
- Clinical observations and other proportion data were analyzed using the Variance Test for Homogeneity of the Binominal Distribution. Quantitative continuous data were analyzed using Barlett´s Test for Homogeneity of Variance and the Analysis of Variance when Barlett´s Test was not significant (p>0.05). If the Analysis of Variance was significant (p>0.05), Dunnett´s Test was used to identify the statistical significance of the individual groups. If the Analysis of Variance was not appropriate, the Kruskal-Wallis Test was used when >75% ties were present. In case of significance (p>0.05), Dunn´s Method of Multiple Comparisons was used for identification of statistical significance of the individual groups.
- Historical control data:
- No details.
One dam having a litter consisting of seven early resorptions was pointed out as single non-dosage dependent event and to be within the ranges observed historically at the test facility. - Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- effects observed, treatment-related
- Description (incidence and severity):
- The two highest dose levels caused some local irritation at the site of application.
- Mortality:
- no mortality observed
- Description (incidence):
- Two animals in the control group and one animal in the high-dose group died within 6 h after first application; these were not considered to be treatment related and the animals were replaced.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No decreases in maternal weight gain.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No decreases in feed consumption
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Necropsy findings were limited to skin flaking and scabbing first identified in life and observations related to wearing the Elizabethan collar (local alopecia, chromorhinorrhea, and neck lesions).
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
- Number of abortions:
- not specified
- Pre- and post-implantation loss:
- not specified
- Total litter losses by resorption:
- not specified
- Early or late resorptions:
- not specified
- Dead fetuses:
- not specified
- Changes in pregnancy duration:
- not specified
- Changes in number of pregnant:
- not specified
- Other effects:
- not specified
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: local irritation
One dam of the mid-dose goup (1/25) having a litter consisting of seven early resorptions was pointed out as single non-dosage dependent event and to be within the ranges observed historically at the test facility. - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- local
- Effect level:
- 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- There were no significant differences from control in fetal weight.
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- There were no significant differences from control in embryo/fetal viability.
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- There were no significant differences from control in variations. The observed effects in fetuses were dose-independent and regarded to be sporadic.
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- There were no significant differences from control invariations. The observed effects in fetuses were dose-independent and regarded to be sporadic.
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Description (incidence and severity):
- There were no significant differences from control in malformations, or variations. The observed effects in fetuses were dose-independent and regarded to be sporadic.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- There were no significant differences from control in malformations, or variations. The observed effects in fetuses were dose-independent and regarded to be sporadic.
- Description (incidence and severity):
- There were no significant differences from control in malformations, or variations. The observed effects in fetuses were dose-independent and regarded to be sporadic.
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects: The observed effects in fetuses were dose-independent and regarded to be sporadic. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
- Key result
- Abnormalities:
- not specified
- Key result
- Developmental effects observed:
- not specified
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions (15 dams per group instead of 20, administration on day 0-19 of gestation, limited details on study design)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- (only 15 presumed pregnant females per group, exposure on day 0-19 of gestation, only 2 dose levels, nonstandard dermal exposure, limited details on exposure)
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Kingston, N.Y.
- Age at study initiation: approx. 9 weeks
- Mean weight at study initiation: 248 g
- Diet: Purina Certified Rodent Chow #5002 (Meal), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 22
- Humidity (%): 40 - 60
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- dermal
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Type of wrap if used: open exposure, no wrap
- Time intervals for shavings or clipplings: no data on frequency; clipped, intact skin
- Site: dorsal
Controls: The rats of the control group were clipped and collared. The intact dorsal skin of each rat was stroked with the tip of a syringe, but no test material was applied.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): no
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): The amount of the test material applied with a syringe was calculated based on the body weight of the animals and the density of the test substance.
USE OF RESTRAINERS FOR PREVENTING INGESTION: yes. To minimize ingestion of the test material, the rats were fitted with cardboard Elizabethan-style collars. - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused: M/F ratio per cage: 1/1
- Proof of pregnancy: vaginal plug / sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- gestation days 0 - 19
- Frequency of treatment:
- daily
- Duration of test:
- The animals were sacrificed on day 20 of gestation.
- Remarks:
- Doses / Concentrations:
800 and 2000 mg/kg bw/day
Basis:
nominal conc. - No. of animals per sex per dose:
- 15 presumed-pregnant females
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: based on results of a 13-week dermal study previously conducted with the same material
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once daily
- Cage side observations checked: signs of pathosis, abortion, premature delivery, and death
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes
- Time schedule for examinations: day 0, 3, 6, 10, 13, 16, and 20 of gestation
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
- Time schedule for calculation: days 0-3, 3-6, 6-10, 10-13, 13-16, and 16-20
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: The thoracic and abdominal cavities were exposed and all organs were examined grossly for evidence of pathosis.
OTHER:
- Clinical chemistry: alanine aminotransferase (ALT), albumin, albumin/globulin ration, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bilirubin, calcium, chloride, cholesterol, creatinine, globuline, glucose, iron, lactate dehydrogenase (LDH), phosphorus, potassium, sodium, sorbitol dehydrogenase (SDH), total protein, triglycerides, urea nitrogen, and uric acid - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Number of live and dead fetuses: Yes
- Other: The ovaries of non-pregnant females were grossly examined and then discarded. - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: No - Statistics:
- - Analysis of variances and group comparison using Fisher's Exact or Dunnett's test (maternal biophase and cesarean section data, and fetal data)
- ANOVA and Fisher's Exact test (fetal skeletal data)
- Fisher's Exact test (fetal visceral data)
- SAS procdures, Student-Newman-Keul's multiple comparison test (clinical chemistry data)
P < 0.05 - Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- effects observed, treatment-related
- Description (incidence and severity):
- - General observations: neck lesions, red nasal exudate, and chromodacryorrhea in all groups (considered not to be test substance-related as these signs are common in animals that are collared)
- Local effects: mild dermal irritation including erythema and flaking of the skin in the treatment groups - Mortality:
- not specified
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- similar to controls in both treatment groups
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- similar to control in both treatment groups; only difference (statistically significant) in high dose group on day 13-16: 31.5 g vs. 29.5 g (corresponding control data)
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- no differences between treated and non-treated rats were observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- no remarkable findings were observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
- Number of abortions:
- no effects observed
- Description (incidence and severity):
- no parameter evaluated appeared to be adversely affected
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- no parameter evaluated appeared to be adversely affected
- Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- no parameter evaluated appeared to be adversely affected
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- no parameter evaluated appeared to be adversely affected
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- no parameter evaluated appeared to be adversely affected
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- no parameter evaluated appeared to be adversely affected
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- no parameter evaluated appeared to be adversely affected
- Other effects:
- not specified
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: slight local effects
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Mean fetal body weights and crown-rump lengths, parameters of body growth and development were normal compared to controls.
- Reduction in number of live offspring:
- not specified
- Changes in sex ratio:
- not specified
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- not specified
- External malformations:
- no effects observed
- Description (incidence and severity):
- No malformations or variations were observed. Bruises were observed on the skin of 4 fetuses from the control group and 2 fetuses form the 800 mg/kg bw/day group (considered to be incidental). One fetus from one dam exposed to 800 mg/kg bw/day was pale in colour. No other remarkable findings were observed during external examination.
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Malformations (lumbar and sacral vertebrae, tail, sternebrae, and ribs) were observed. The incidence was low and there was no apparent dose-response relationship, these effects were considered to be not treatment-related. Comparable incidences of variant skeletal development were observed in both cotnrol and trated fetuses.
- Visceral malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- A statistically significant (high dose) increase in the number of fetuses with levocardia was observed. The response appeared to be dose-related
Levocardia:
Litters: control: 0 (0%); 800 mg/kg bw/day: 2 (14.3%); 2000 mg/kg bw/day: 7 (50%); 14 litters per group examined
Fetuses: control: 0 (0%); 800 mg/kg bw/day: 3 (3.2%); 2000 mg/kg bw/day: 7 (10.1%); 94, 93, and 99 fetuses examined, respectively
Microphthalmia, anophtalmia and "apparent" hydronephrosis were also observed. Variant visceral development was observed in control and treated fetuses. - Other effects:
- not specified
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- developmental
- Effect level:
- 800 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- < 800 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
- Key result
- Abnormalities:
- not specified
- Key result
- Developmental effects observed:
- not specified
- Conclusions:
- In a developmental toxicity study, pregnant rats were dermally exposed to the test substance. No adverse effects were observed in any maternal or reproductive parameter nor on external and skeletal development of fetuses. Levocardia was observed in 3.2% and 10.1% of the fetuses exposed in utero to 800 and 2000 mg/kg bw /day, respectively. Thus, the developmental NOAEL was determined to be < 800 mg/kg bw.
Referenceopen allclose all
Table 1: Skin reaction observations
|
0 mg/kg bw/d |
200 mg/kg bw/d |
600 mg/kg bw/d |
2000 mg/kg bw/d |
Maximum possible incidencesa |
375/25 |
375/25 |
375/25 |
375/25 |
Erythema |
||||
Total |
0/0 |
2/1 |
22/4 |
91/13b |
Grade 1 |
0/0 |
2/1 |
10/4 |
81/13b |
Grade 2 |
0/0 |
0/0 |
4/1 |
10/4b |
Flaking |
||||
Total |
11/3 |
15/2 |
55/6 |
170/17 b |
Grade 1 |
11/3 |
9/2 |
27/5 |
61/14 b |
Grade 2 |
0/0 |
6/1 |
19/4 |
71/14b |
Grade 3 |
0/0 |
0/0 |
9/1 |
38/7 b |
Edema |
||||
Total |
0/0 |
0/0 |
23/4 |
83/11b |
Grade 1 |
0/0 |
0/0 |
18/4 |
59/11b |
Grade 2 |
0/0 |
0/0 |
5/1 |
24/6b |
Scab |
0/0 |
0/0 |
6/2 |
19/4 |
a: Maximum incidence : Days x rats from first treatment on GD 6 through sacrifice on GD 20 divided by the number of rats examined per group on GD 6-20
b: Significantly different from vehicle control group value (p≤0.01)
Table 2: Maternal reproductive, litter, and fetal alteration observations: Caesarian-Section results on GD 20
|
0 mg/kg bw/d |
200 mg/kg bw/d |
600 mg/kg bw/d |
2000 mg/kg bw/d |
Rats pregnant and sectioned on Day 20 of gestation (n) |
25 |
23 |
22b |
24 |
Corpora lutea/dam |
16.4 |
16.6 |
16.9 |
16.5 |
Implantation sites/litter |
15.0 |
15.4 |
14.9 |
14.2 |
Litter size |
||||
Live fetuses/litter |
14.6 |
14.6 |
14.0 |
13.3 |
Live fetuses (n) |
364 |
335 |
308 |
320 |
Dead fetuses (n) |
0 |
0 |
0 |
0 |
Resorptions |
0.4 |
0.9 |
0.9 |
0.9 |
Early (n) |
10 |
20 |
19 |
21 |
Late (n) |
1 |
0 |
0 |
0 |
Dams with any resorptions n(%) |
9 (36) |
11 (48) |
15 (68) |
11 (46) |
% resorbed/litter |
2.9 |
5.4 |
5.8 |
5.0 |
% male/litter |
51.3 |
50.8 |
48.1 |
47.7 |
Live fetal body weight (g/litter) |
3.68 |
3.62 |
3.69 |
3.75 |
Male |
3.77 |
3.68 |
3.82 |
3.85 |
Female |
3.58 |
3.56 |
3.58 |
3.65 |
Fetuses evaluated (n) |
364 |
335 |
308 |
320 |
Litters with any alterations observed n(%) |
10 (40) |
8 (35) |
14 (64) |
7 (25) |
Fetuses with any alterations observed n(%) |
13 (3.5) |
10 (3.0) |
20 (6.5) |
9 (2.0) |
% fetuses/litter with any alterations observed |
3.5 |
2.9 |
6.8c |
2.7 |
b: Excludes values for one dam, which had a litter consisting of seven early resorptions.
c: Significantly different from vehicle control group value (p≤0.05)
Table 3: Fetal evaluations
|
0 mg/kg bw/d |
200 mg/kg bw/d |
600 mg/kg bw/d |
2000 mg/kg bw/d |
Litters evaluated |
25 |
23 |
22b |
24 |
Fetuses evaluated |
364 |
335 |
308 |
320 |
Live |
364 |
335 |
308 |
320 |
Fetal gross external alterations |
364 |
335 |
308 |
320 |
Tail: kinked |
||||
Litter incidence, n (%) |
0(0) |
1 (4.3) |
0(0) |
0(0) |
Fetal incidence, n (%) |
0(0) |
1(0.3) |
0(0) |
0(0) |
Body: hematoma |
||||
Litter incidence, n (%) |
1(4.0) |
0(0) |
0(0) |
0(0) |
Fetal incidence, n (%) |
1 (0.3) |
0(0) |
0(0) |
0(0) |
Fetal soft tissue alterations, evaluations |
174 |
162 |
149 |
155 |
Vessels: umbilical artery descended to the left of urinary bladder |
||||
Litter incidence, n (%) |
2(8.0) |
3(13.0) |
2(9.1) |
2(8.3) |
Fetal incidence, n (%) |
2(1.1) |
3(1.8) |
3(2.0) |
2(1.3) |
Vessels: apparent additional umbilical artery descended left of the bladder |
||||
Litter incidence, n (%) |
0(0) |
0(0) |
1(4.5) |
0(0) |
Fetal incidence, n (%) |
0(0) |
0(0) |
1(0.7) |
0(0) |
Fetal skeletal alterations, evaluations |
190 |
173 |
159 |
165 |
Cervical vertebrae: cervical rib present at 7th cervical vertebrae |
||||
Litter incidence, n (%) |
2(8.0) |
1(4.3) |
1(4.8) |
0(0) |
Fetal incidence, n (%) |
2(1.0) |
2(1.2) |
1(1.2) |
0(0) |
Thoracic vertebrae: centrum, bifid |
||||
Litter incidence, n (%) |
1(4.0) |
1(4.3) |
5(22.7) |
0(0) |
Fetal incidence, n (%) |
1(0.5) |
1(0.6) |
5(3.1)a |
0(0) |
Lumbar vertebrae: centrum, bifid |
||||
Litter incidence, n (%) |
0(0) |
1(4.3) |
0(0) |
0(0) |
Fetal incidence, n (%) |
0(0) |
1(0.6) |
0(0) |
0(0) |
Ribs: wavy |
||||
Litter incidence, n (%) |
0(0) |
0(0) |
2(9.1) |
1(4.2) |
Fetal incidence, n (%) |
0(0) |
0(0) |
2(1.2) |
1(0.5 |
Sternal centra: 1st, not ossified |
||||
Litter incidence, n (%) |
1(4.0) |
0(0) |
0(0) |
2(8.3) |
Fetal incidence, n (%) |
1(0.5) |
0(0) |
0(0) |
2(1.3) |
Sternal centra: 1st, incompletely ossified |
||||
Litter incidence, n (%) |
3(12.0) |
3(13.0) |
2(5.1) |
1(4.2) |
Fetal incidence, n (%) |
4(2.1) |
4(2.3) |
2(1.2) |
1(0.6) |
Pelvis: pubis, incompletely ossified |
||||
Litter incidence, n (%) |
3(12.0) |
0(0) |
4(18.2) |
3(12.5) |
Fetal incidence, n (%) |
3(1.6) |
0(0) |
5(3.1) |
3(1.8) |
Pelvis: ischium, incompletely ossified |
||||
Litter incidence, n (%) |
0(0) |
0(0) |
2(9.1) |
0(0) |
Fetal incidence, n (%) |
0(0) |
0(0) |
2(1.2) |
0(0) |
a: Significantly different from vehicle control group (p≤0.01)
Levocardia was the only parameter affected in fetuses of dams treated with the test substance during gestation. In other studies, levocardia was observed in control fetuses, too. However, the effect of the test substance on heart development should be focused on in further studies as well as the impact, this effect has on postnatal survival.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 800 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rabbit
- Quality of whole database:
- K2
Toxicity to reproduction: other studies
Additional information
Developmental toxicity
CAS 11138-60-6
Fatty acids, 8-10 (even numbered), di- and triesters with propylidynetrimethanol (CAS 11138-60-6) was tested in a prenatal developmental toxicity study comparable to OECD Guideline 414 (Azuka and Daston, 2004). The test substance was percutaneously applied to Sprague-Dawley rats for 6 h/day under occlusive conditions. 25 animals per sex per dose were treated with 200, 600 or 2000 mg/kg bw/day in corn oil on Days 6-15 of gestation. Control animals (25 per sex per dose) received the vehicle. The middle and the high dose levels caused some local irritation at the site of application, but no decreases in maternal weight gain or food consumption. There were no differences from control in any of the developmental parameters measured, including embryo/fetal viability, fetal weight, malformations, or variations. Therefore, a NOAEL of 2000 mg/kg bw/day was derived for prenatal development and for systemic maternal toxicity. Due to the irritation effects on skin, the local maternal NOAEL was found to be 200 mg/kg bw/day.
CAS 67762-53-2
The developmental toxicity of Fatty acids, C5-9, tetraesters with pentaerythritol (CAS 67762-53-2) was investigated comparable to OECD Guideline 414 (prenatal developmental toxicity study) (Feusten, 1988). Groups of 15 presumed pregnant female Sprague-Dawley rats received daily dermal doses of the test substance at concentrations of 800 and 2000 mg/kg bw/day during gestational days 0 to 19. Control animals remained untreated. On day 20 of gestation the animals were euthanized and examined for maternal and fetal parameters. There were no adverse effects found for all parameters examined in maternal animals. Based on the number of implantations, number of total litter losses by resorption, mortality, clinical signs, body weight, gross pathology and organ weights of maternal animals the NOAEL for maternal toxicity was found to be 2000 mg/kg bw/day. Examination of fetus litter size and weights, offspring viability (number alive and number dead), sex ratio, grossly visible abnormalities, external, head, soft tissue and skeletal abnormalities revealed no differences to controls and thus no indication for teratogenic effects. The only effect found was a dose-dependently increased number of fetuses with levocardia, although no hearth malformations have been detected. Furthermore levocardia was observed in vehicle control foetuses (Smith et al. 1988) and in the control foetuses conducted in the test laboratory. Since levocardia was observed in both treated groups, the NOAEL for embryo-/fetotoxicity and teratogenicity in rats Fatty acids, C5-9, tetraesters with pentaerythritol was found to be < 800 mg/kg bw/day and the LOAEL = 800 mg/kg bw/day.
A waiver for the requirement to perform a prenatal developmental toxicity study in a 2nd species was included, as this requirement is considered not to add new information for hazard assessment and therefore is scientifically and, considering concerns regarding the use of vertebrate animals for experimental purposes, unjustified.
Justification for classification or non-classification
Based on the information present from the read-across substances, the substance is not anticipated to induce effects that would affect the reproductive and developmental parameters, therefore in accordance with Regulation 1272/2008, the substance is not classified for reproduction or development toxicity.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.